AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04533217 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vertebroplasty
Description: Injection of cement into vertebral lesion(s)
Study NCT04296942 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brachyury-TRICOM
Description: Every three weeks, until cycle 9, then every 12 weeks: \*Recombinant MVA-Bavarian Nordic (BN)-Brachyury recommended phase 2 dose (R2PD): 4 injections of vaccines with 1 given subcutaneous (SC) in each extremity on Day 1 of Cycles 1 and 2. Each injection of MVA-BN-Brachyury consists of 2.0 x 10\^8 infectious units (Inf.U). \*Recombinant fowlpox virus (FPV)-BN-Brachyury: 1 injection given SC in one extremity on Day 1 of Cycles 3 and beyond. Each injection of FPV-BN-Brachyury consists of 1.0 x 10\^9 Inf.U.
Study NCT04296942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: 5mg by mouth weekly (RP2D) administered by patient on Days 1, 8 and 15 of each cycle.
Study NCT04296942 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M7824
Description: 1800mg via intravenous (IV) infusion every (q)3 weeks on Day 1 of each cycle.
Study NCT04296942 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ado-trastuzumab emtansine
Description: 3.6mg/kg via intravenous (IV) infusion every (q)3 weeks on Day 1 of each cycle.
Study NCT06495411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pranayama-
Description: Pain of patients will be evaluated with the Visual analog scale at the 6th hour, 12th hour, 24th hour and at discharge.
Study NCT06495411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deep breathing-
Description: Pain of patients will be evaluated with the Visual analog scale at the 6th hour, 12th hour, 24th hour and at discharge.
Study NCT06495411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control
Description: Pain of patients will be evaluated with the Visual analog scale at the 6th hour, 12th hour, 24th hour and at discharge.
Study NCT05224687 — intervention group
Intervention type: OTHER
Intervention: Retroactive review of patient data of those receiving a dose of daptomycin
Description: A retrospective analysis will be conducted using patient data of those receiving a dose of daptomycin at MCMC, Methodist Dallas Medical Center, Methodist Richardson Medical Center, or Methodist Mansfield Medical Center.
Study NCT05122403 — intervention group
Intervention type: PROCEDURE
Intervention: MRgFUS central lateral thalamotomy
Description: MRgFUS central lateral thalamotomy is a minimally invasive and effective procedure for medication-refractory neuropathic pain patients.
Study NCT06201065 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepatic arterial infusion chemotherapy
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
Study NCT06201065 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
Study NCT06201065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing
Study NCT06184880 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioral
Description: International Physical Activity (IPAQ) Questionnaire, Quality of Life Questionnaire QLQ-C30, HN 43 questionnaire, Multidimensional Fatigue Inventory (MFI) Questionnaire, Big Five Inventory Questionnaire, illness Identity Questionnaire,
Study NCT06184880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral
Description: International Physical Activity (IPAQ) Questionnaire, Quality of Life Questionnaire QLQ-C30, HN 43 questionnaire, Multidimensional Fatigue Inventory (MFI) Questionnaire, Big Five Inventory Questionnaire, illness Identity Questionnaire,
Study NCT06184880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sedentary
Description: Actimetry (cumulative time without movement over 24h, prolonged sedentary periods >30 min without movement. Continuous recording 7 days prior to visit T0, T1, T2, T3, T4, T5
Study NCT06184880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sedentary
Description: Actimetry (cumulative time without movement over 24h, prolonged sedentary periods >30 min without movement. Continuous recording 7 days prior to visit T0, T1, T2, T3, T4, T5
Study NCT06201065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing
Study NCT06201065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240 mg iv.drip Q3W
Study NCT05752838 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is a survey study, and there were no intervention
Study NCT06201065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin , fluorouracil, and leucovorin
Description: FOLFOX-HAIC
Study NCT06440317 — intervention group
Intervention type: DEVICE
Intervention: Hemofiltration membranes (the oXiris membrane® and the HF1400® membrane)
Description: The PRISMAFLEX® or PRISMAX® control unit (pre- and post-dilution with a prescribed treatment dose > 25 ml/kg/h) with regional citrate anticoagulation and a substitution solution by PHOXILLUM will be used regardless of the type of membrane used (the oXiris membrane and the HF 1400 membrane), also as part of routine care provided in the ICU.
Study NCT05265845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention aims to support infant feeding decisions and teach responsive feeding strategies.
Study NCT05265845 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text4Baby
Description: Free health and wellness text messages timed to due date through pregnancy and up until the baby's first birthday.
Study NCT04747808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LL-BMT1
Description: Drug-printed contact lens in both eyes
Study NCT05583344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4532990
Description: GSK4532990 will be administered.
Study NCT05583344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study NCT05327959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clavicle open reduction and internal fixation
Description: Clavicle open reduction and internal fixation using the A.L.P.S. Clavicle Plating System
Study NCT06252987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine treatment
Description: Routine medical treatment, basic rehabilitation training and individualized cognitive training
Study NCT06252987 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: routine treatment
Description: Routine medical treatment, basic rehabilitation training and individualized cognitive training
Study NCT04349514 — intervention group
Intervention type: OTHER
Intervention: Natural history
Description: Longitudinal observation of neuroimaging, clinical, and blood markers.
Study NCT05057715 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VCN-01
Description: Intravenous administration of VCN-01
Study NCT05057715 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: huCART-meso Cells
Description: Intravenous administration of huCART-meso cells
Study NCT06313008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: eligible subjects were randomly and equally assigned to the empagliflozin add-on group (empagliflozin 10 mg/ day).
Study NCT06313008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 MG
Description: eligible subjects were randomly and equally assigned to vildagliptin add-on group (vildagliptin 50 mg/day as the initial dose).
Study NCT06462547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INZ-701
Description: INZ-701 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody (rhENPP1-Fc).
Study NCT05048082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegsitacianine
Description: An intraoperative nanoparticle-based fluorescence imaging agent comprised of micelles covalently conjugated to indocyanine green (ICG).
Study NCT05048082 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor resection surgery
Description: Standard of care surgical removal of cancerous lung lesion
Study NCT06252987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-invasive brain stimulation
Description: tDCS\&rTMS
Study NCT06201065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin , fluorouracil, and leucovorin
Description: FOLFOX-HAIC
Study NCT05078385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGLE-102
Description: AGLE-102, bone marrow mesenchymal stem cell derived extracellular vesicles (EVs)
Study NCT05538858 — intervention group
Intervention type: PROCEDURE
Intervention: Mechanical Ventilation
Description: Positive pressure mechanical ventilation
Study NCT04753359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Med
Description: Mediterranean diet
Study NCT04842721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic Saturated Saline Mouth Rinse Active Arm
Description: Each Patient of this groups will be asked to keep the solution still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing. After 30 minutes the solution will be spit out and mouth will be rinsed with plain water several times. The process will be done twice a day for 2 days.
Study NCT04842721 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Plain Water Mouth Rinse Arm
Description: Each Patient of this groups will be asked to keep the water still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing. After 30 minutes the water will be spit out. The process will be done twice a day for 2 days.
Study NCT05301322 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF Vaccine
Description: RSV Vaccine
Study NCT05301322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT05301322 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Inactivated Influenza Vaccine
Description: SIIV
Study NCT04753359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WL
Description: Measuring change in weight
Study NCT05286112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Description: 10 sessions focused on increasing mindfulness awareness to address thoughts, emotions, and behaviors that maintain functional impairment and risk of suicide.
Study NCT05286112 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
Study NCT05629416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interventions to transform the culture of healthcare systems to achieve excellence in providing culturally safe care for First Nations peoples
Description: 1. Implement 'Ask the Specialist Plus', a structured program to promote anti-racism within Northern Territory (NT) hospitals by giving healthcare providers training in cultural safety.~2. Implement strategies to foster 'Clinical champions of cultural safety' through a social media chat platform and face to face meetings to discuss anti-racism practice, cultural safety and practical ways to deliver culturally safe care including interpreter use.~3. Support simplified and improved strategies for booking an interpreter to increase uptake.~4. Implement retention strategies to ensure interpreters receive workplace support.~5. Provide training in health terminology for interpreters.~6. Integrate interpreter supply and demand through efficiency and effectiveness strategies tailored to participating sites.~7. Implement continuous quality improvement cycles with senior managers, using findings from qualitative and quantitative data collection and evaluation.
Study NCT06274528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Description: Within FDA approved dose 10 mg; capsule; QD, 6 month duration
Study NCT06274528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 20mg
Description: 20 mg; capsule; QD; 6 month duration
Study NCT06274528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg; capsule; QD; 6 month duration
Study NCT04703218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: olfactory rehabilitation
Description: Olfactory rehabilitation consists of smelling 4 scents twice a day using scent sticks, for 12 weeks
Study NCT05622370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam tablets (50mg/ tablet, BRIVIACT®, UCB)
Description: Brivaracetam tablets (trade name: Briviact) Specification: 50mg/ piece Batch number: 34244 Content: 100.0% Date of purchase: September 2022~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach.~Expiry date: April 2025 Storage conditions: sealed, stored at 20-25℃, allowing short-term temperature deviation of 15-30℃ Manufacturer: Union Chimique Belge Pharm, UCB Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd.
Study NCT05622370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam sustained-release tablets 100mg
Description: Brivaracetam sustained-release tablets Specification: 100mg/ tablet Batch number: 22081201 Content: 102.5% Date of production: August 12, 2022 Expiry date: August 11th, 2024. Storage conditions: sealed and stored at 10-30℃ Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd.~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach.
Study NCT05622370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brivaracetam sustained-release tablets 100mg
Description: Brivaracetam sustained-release tablets Specification: 100mg/ tablet Batch number: 22081201 Content: 102.5% Date of production: August 12, 2022 Expiry date: August 11th, 2024. Storage conditions: sealed and stored at 10-30℃ Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd.~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach.
Study NCT05622370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam sustained-release tablets 50mg
Description: Brivaracetam sustained-release tablets Specification: 50mg/ piece Batch number: 22082501 Content: 100.0% Date of production: September 02, 2022 Expiry date: August 24th, 2024. Storage conditions: sealed and stored at 10-30℃ Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd.~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach.
Study NCT05622370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brivaracetam sustained-release tablets 50mg
Description: Brivaracetam sustained-release tablets Specification: 50mg/ piece Batch number: 22082501 Content: 100.0% Date of production: September 02, 2022 Expiry date: August 24th, 2024. Storage conditions: sealed and stored at 10-30℃ Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd.~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach.
Study NCT04824365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Pyruvate
Description: Subjects will use a sodium pyruvate nasal spray 3x daily for 14 days.
Study NCT04824365 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Subjects will use a saline nasal spray 3x daily for 14 days.
Study NCT05123911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational Shampoo
Description: Parent/LAR will bathe the child participant with the investigational shampoo at least 3 times a week for up to 28 days.
Study NCT05123911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational Conditioner
Description: Parent/LAR will bathe the child participant with the investigational conditioner at least 3 times a week for up to 28 days.
Study NCT05123911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational Combing Cream
Description: Parent/LAR will apply investigational combining cream to wet and previously moistened hair at least 3 times a week for up to 28 days.
Study NCT04892810 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous ablation
Description: Hepatic Percutaneous Ablation with radiofrequency or microwave
Study NCT06113016 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT06113016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT06453837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mentha Suaveolens extract incorporated into a food supplement
Description: Each subject of this group takes 1 capsule of the food supplement per day, with lunch, for 84 consecutive days.
Study NCT06453837 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo product
Description: Each subject of this group takes 1 capsule of comparator product per day, with lunch, for 84 consecutive days.
Study NCT05318755 — intervention group
Intervention type: DRUG
Intervention: GAHT for transgender men
Description: Testosterone undecanoate
Study NCT05318755 — intervention group
Intervention type: DRUG
Intervention: GAHT for transgender women
Description: Estradiol and antiandrogens (Spironolactone or Cyproterone acetate)
Study NCT05983627 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Umbilical Cord Mesenchymal Stem Cells
Description: The stem cell infusion route is peripheral intravenous infusion. All subjects received experimental drugs and conventional treatment during the study period.
Study NCT05894031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wim Hof Method
Description: The intervention followed the guidelines provided by Wim Hof. The intervention comprised three components: cold water exposure, breathing exercise, and meditation.The participants were instructed to perform the WHM daily over the course of 15 days. The participants could choose when to do so throughout the day, however, the components were to be performed in a strict, sequential order: breathing exercises, followed by meditation, and then cold exposure. Participants were asked to complete a daily log in which they documented whether they performed the procedure and for how long. Altogether, the procedure lasted about 15 minutes.
Study NCT02190786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUX-1151
Study NCT06113016 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive handout on physical activity
Study NCT06113016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Receive individually tailored exercise intervention
Study NCT06113016 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Receive individually tailored exercise intervention
Study NCT06113016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fisetin
Description: Given PO
Study NCT06113016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fisetin
Description: Given PO
Study NCT06113016 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Performance Testing
Description: Ancillary studies
Study NCT06113016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Ancillary studies
Study NCT06113016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT05006833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Provider Training - Bundled Approach
Description: At each clinic randomized to bundled training, providers will be invited to participate in one, in-clinic, group-based training. Each training will last one-hour and providers will receive continuing medical education (CME) credit for participating. Trainings will focus on introducing the HPV vaccine in a bundle of the other two adolescent vaccines (Tdap and MenACWY).
Study NCT06113016 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT06113016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies